{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:44:47Z","timestamp":1791931487706,"version":"4.3.4"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Innogen Pharmaceutical Co., Ltd., Shanghai China"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"DOI":"10.1007\/s40262-026-01713-6","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:45:39Z","timestamp":1791927939000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efsubaglutide Alfa: A Comprehensive Pharmacological Review"],"prefix":"10.1007","author":[{"given":"Haolin","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald J.","family":"Prud\u2019homme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6478-0988","authenticated-orcid":false,"given":"Qinghua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"1713_CR1","doi-asserted-by":"publisher","first-page":"1293926","DOI":"10.3389\/fcdhc.2023.1293926","volume":"4","author":"L Ferhatbegovi\u0107","year":"2023","unstructured":"Ferhatbegovi\u0107 L, Mr\u0161i\u0107 D, Maci\u0107-D\u017eankovi\u0107 A. The benefits of GLP1 receptors in cardiovascular diseases. Front Clin Diabetes Healthc. 2023;4:1293926. https:\/\/doi.org\/10.3389\/fcdhc.2023.1293926.","journal-title":"Front Clin Diabetes Healthc"},{"key":"1713_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102782","volume":"75","author":"N Alfaris","year":"2024","unstructured":"Alfaris N, et al. GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review. EClinicalMedicine. 2024;75:102782. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102782.","journal-title":"EClinicalMedicine"},{"issue":"12","key":"1713_CR3","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.1172\/JCI97233","volume":"127","author":"DJ Drucker","year":"2017","unstructured":"Drucker DJ, Habener JF, Holst JJ. Discovery, characterization, and clinical development of the glucagon-like peptides. J Clin Invest. 2017;127(12):4217\u201327. https:\/\/doi.org\/10.1172\/JCI97233.","journal-title":"J Clin Invest"},{"issue":"S1","key":"1713_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/jdi.12466","volume":"7","author":"D D'Alessio","year":"2016","unstructured":"D\u2019Alessio D. Is GLP-1 a hormone: whether and when? J Diabet Invest. 2016;7(S1):50\u20135. https:\/\/doi.org\/10.1111\/jdi.12466.","journal-title":"J Diabet Invest"},{"key":"1713_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.peptides.2013.01.014","volume":"44","author":"CS Marathe","year":"2013","unstructured":"Marathe CS, et al. Glucagon-like peptides 1 and 2 in health and disease: a review. Peptides. 2013;44:75\u201386. https:\/\/doi.org\/10.1016\/j.peptides.2013.01.014.","journal-title":"Peptides"},{"issue":"5","key":"1713_CR6","doi-asserted-by":"publisher","first-page":"736","DOI":"10.2967\/jnumed.106.038679","volume":"48","author":"M K\u00f6rner","year":"2007","unstructured":"K\u00f6rner M, et al. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med. 2007;48(5):736\u201343. https:\/\/doi.org\/10.2967\/jnumed.106.038679.","journal-title":"J Nucl Med"},{"issue":"4","key":"1713_CR7","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1210\/en.2013-1934","volume":"155","author":"C Pyke","year":"2014","unstructured":"Pyke C, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology. 2014;155(4):1280\u201390. https:\/\/doi.org\/10.1210\/en.2013-1934.","journal-title":"Endocrinology"},{"issue":"9645","key":"1713_CR8","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","volume":"372","author":"DJ Drucker","year":"2008","unstructured":"Drucker DJ, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(08)61206-4.","journal-title":"Lancet"},{"issue":"1","key":"1713_CR9","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12929-024-01090-x","volume":"31","author":"CT Hong","year":"2024","unstructured":"Hong CT, Chen JH, Hu CJ. Role of glucagon-like peptide-1 receptor agonists in Alzheimer\u2019s disease and Parkinson\u2019s disease. J Biomed Sci. 2024;31(1):102. https:\/\/doi.org\/10.1186\/s12929-024-01090-x.","journal-title":"J Biomed Sci"},{"issue":"4","key":"1713_CR10","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740\u201356. https:\/\/doi.org\/10.1016\/j.cmet.2018.03.001.","journal-title":"Cell Metab"},{"issue":"3","key":"1713_CR11","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1210\/jcem.87.3.8355","volume":"87","author":"MA Nauck","year":"2002","unstructured":"Nauck MA, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87(3):1239\u201346. https:\/\/doi.org\/10.1210\/jcem.87.3.8355.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1713_CR12","doi-asserted-by":"publisher","first-page":"785","DOI":"10.2337\/diab.46.5.785","volume":"46","author":"RS Heller","year":"1997","unstructured":"Heller RS, Kieffer TJ, Habener JF. Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas. Diabetes. 1997;46(5):785\u201391. https:\/\/doi.org\/10.2337\/diab.46.5.785.","journal-title":"Diabetes"},{"issue":"6","key":"1713_CR13","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"LL Baggio","year":"2007","unstructured":"Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131\u201357. https:\/\/doi.org\/10.1053\/j.gastro.2007.03.054.","journal-title":"Gastroenterology"},{"issue":"5","key":"1713_CR14","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1007\/s00125-011-2069-9","volume":"54","author":"M Shimoda","year":"2011","unstructured":"Shimoda M, et al. The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetologia. 2011;54(5):1098\u2013108. https:\/\/doi.org\/10.1007\/s00125-011-2069-9.","journal-title":"Diabetologia"},{"issue":"3","key":"1713_CR15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","volume":"3","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153\u201365. https:\/\/doi.org\/10.1016\/j.cmet.2006.01.004.","journal-title":"Cell Metab"},{"issue":"3","key":"1713_CR16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.4093\/dmj.2025.0106","volume":"49","author":"JS Park","year":"2025","unstructured":"Park JS, Kim KS, Choi HJ. Glucagon-Like Peptide-1 and Hypothalamic Regulation of Satiation: Cognitive and Neural Insights from Human and Animal Studies. Diabetes Metab J. 2025;49(3):333\u201347. https:\/\/doi.org\/10.4093\/dmj.2025.0106.","journal-title":"Diabetes Metab J"},{"issue":"40","key":"1713_CR17","doi-asserted-by":"publisher","first-page":"14821","DOI":"10.3748\/wjg.v20.i40.14821","volume":"20","author":"XC Wang","year":"2014","unstructured":"Wang XC, et al. Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation. World J Gastroenterol. 2014;20(40):14821\u201330. https:\/\/doi.org\/10.3748\/wjg.v20.i40.14821.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1713_CR18","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/bcp.12777","volume":"81","author":"G Luo","year":"2016","unstructured":"Luo G, Liu H, Lu H. Glucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients? Br J Clin Pharmacol. 2016;81(1):78\u201388. https:\/\/doi.org\/10.1111\/bcp.12777.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"1713_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103864","volume":"24","author":"E Bilgin","year":"2025","unstructured":"Bilgin E, Venerito V, Bogdanos DP. Glucagon-Like Peptide-1 (GLP-1) receptor agonists in rheumatology: A review of current evidence and future directions. Autoimmun Rev. 2025;24(9):103864. https:\/\/doi.org\/10.1016\/j.autrev.2025.103864.","journal-title":"Autoimmun Rev"},{"key":"1713_CR20","doi-asserted-by":"publisher","first-page":"1148209","DOI":"10.3389\/fimmu.2023.1148209","volume":"14","author":"SF Mehdi","year":"2023","unstructured":"Mehdi SF, et al. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Front Immunol. 2023;14:1148209. https:\/\/doi.org\/10.3389\/fimmu.2023.1148209.","journal-title":"Front Immunol"},{"key":"1713_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3389\/fphys.2017.00015","volume":"8","author":"J Li","year":"2017","unstructured":"Li J, et al. Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies. Front Physiol. 2017;8:15. https:\/\/doi.org\/10.3389\/fphys.2017.00015.","journal-title":"Front Physiol"},{"issue":"7","key":"1713_CR22","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1210\/jc.2013-3809","volume":"99","author":"T Idorn","year":"2014","unstructured":"Idorn T, et al. Elimination and Degradation of Glucagon-like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide in Patients with End-Stage Renal Disease. J Clin Endocrinol Metab. 2014;99(7):2457\u201366. https:\/\/doi.org\/10.1210\/jc.2013-3809.","journal-title":"J Clin Endocrinol Metab"},{"key":"1713_CR23","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3389\/fendo.2019.00260","volume":"10","author":"JJ Holst","year":"2019","unstructured":"Holst JJ. From the Incretin Concept and the Discovery of GLP-1 to Today\u2019s Diabetes Therapy. Front Endocrinol (Lausanne). 2019;10:260. https:\/\/doi.org\/10.3389\/fendo.2019.00260.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"1713_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012734","volume":"5","author":"Q Wang","year":"2010","unstructured":"Wang Q, et al. Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist. PLoS ONE. 2010;5(9):e12734. https:\/\/doi.org\/10.1371\/journal.pone.0012734.","journal-title":"PLoS ONE"},{"issue":"6","key":"1713_CR25","first-page":"790","volume":"12","author":"E Jimenez-Solem","year":"2010","unstructured":"Jimenez-Solem E, Rasmussen MH, Christensen M, et al. Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes. Curr Opin Mol Ther. 2010;12(6):790\u20137.","journal-title":"Curr Opin Mol Ther"},{"issue":"2","key":"1713_CR26","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/sj.gt.3302836","volume":"14","author":"M Kumar","year":"2007","unstructured":"Kumar M, et al. Gene therapy of diabetes using a novel GLP-1\/IgG1-Fc fusion construct normalizes glucose levels in db\/db mice. Gene Ther. 2007;14(2):162\u201372. https:\/\/doi.org\/10.1038\/sj.gt.3302836.","journal-title":"Gene Ther"},{"issue":"12","key":"1713_CR27","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/sj.gt.3302944","volume":"14","author":"N Soltani","year":"2007","unstructured":"Soltani N, et al. In vivo expression of GLP-1\/IgG-Fc fusion protein enhances beta-cell mass and protects against streptozotocin-induced diabetes. Gene Ther. 2007;14(12):981\u20138. https:\/\/doi.org\/10.1038\/sj.gt.3302944.","journal-title":"Gene Ther"},{"key":"1713_CR28","doi-asserted-by":"publisher","first-page":"930","DOI":"10.3389\/fphys.2019.00930","volume":"10","author":"L Ren","year":"2019","unstructured":"Ren L, et al. Novel GLP-1 Analog supaglutide Stimulates Insulin Secretion in Mouse and Human Islet Beta-Cells and Improves Glucose Homeostasis in Diabetic Mice. Front Physiol. 2019;10:930. https:\/\/doi.org\/10.3389\/fphys.2019.00930.","journal-title":"Front Physiol"},{"issue":"1","key":"1713_CR29","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s13098-024-01513-7","volume":"16","author":"Q Wang","year":"2024","unstructured":"Wang Q, et al. supaglutide alleviates hepatic steatosis in monkeys with spontaneous MASH. Diabetol Metab Syndr. 2024;16(1):303. https:\/\/doi.org\/10.1186\/s13098-024-01513-7.","journal-title":"Diabetol Metab Syndr"},{"key":"1713_CR30","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3389\/fphys.2017.00294","volume":"8","author":"Y Wan","year":"2017","unstructured":"Wan Y, et al. Novel GLP-1 Analog supaglutide Reduces HFD-Induced Obesity Associated with Increased Ucp-1 in White Adipose Tissue in Mice. Front Physiol. 2017;8:294. https:\/\/doi.org\/10.3389\/fphys.2017.00294.","journal-title":"Front Physiol"},{"issue":"9","key":"1713_CR31","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s00125-002-0828-3","volume":"45","author":"Q Wang","year":"2002","unstructured":"Wang Q, Brubaker PL. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db\/db mice. Diabetologia. 2002;45(9):1263\u201373. https:\/\/doi.org\/10.1007\/s00125-002-0828-3.","journal-title":"Diabetologia"},{"issue":"3","key":"1713_CR32","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s00125-004-1327-5","volume":"47","author":"Q Wang","year":"2004","unstructured":"Wang Q, et al. Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia. 2004;47(3):478\u201387. https:\/\/doi.org\/10.1007\/s00125-004-1327-5.","journal-title":"Diabetologia"},{"issue":"2","key":"1713_CR33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1530\/JOE-20-0255","volume":"248","author":"Q Cui","year":"2021","unstructured":"Cui Q, et al. Novel GLP-1 analog supaglutide improves glucose homeostasis in diabetic monkeys. J Endocrinol. 2021;248(2):145\u201354. https:\/\/doi.org\/10.1530\/JOE-20-0255.","journal-title":"J Endocrinol"},{"key":"1713_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2022.106218","volume":"175","author":"Y Liao","year":"2022","unstructured":"Liao Y, et al. Pharmacokinetic and pharmacodynamic studies of supaglutide in rats and monkeys. Eur J Pharm Sci. 2022;175:106218. https:\/\/doi.org\/10.1016\/j.ejps.2022.106218.","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"1713_CR35","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s40262-025-01475-7","volume":"64","author":"Y-R Lou","year":"2025","unstructured":"Lou Y-R, et al. Population Pharmacokinetics of efsubaglutide alfa in Healthy Subjects and Subjects with Type 2 Diabetes. Clin Pharmacokinet. 2025;64(4):533\u201352. https:\/\/doi.org\/10.1007\/s40262-025-01475-7.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"1713_CR36","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1111\/dom.16452","volume":"27","author":"Q Wang","year":"2025","unstructured":"Wang Q, et al. Safety, pharmacokinetics and pharmacodynamics of efsubaglutide alfa in healthy participants: A randomised, dose-escalation phase 1 study. Diabetes Obes Metab. 2025;27(8):4220\u20138. https:\/\/doi.org\/10.1111\/dom.16452.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"1713_CR37","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s40262-025-01541-0","volume":"64","author":"X Wu","year":"2025","unstructured":"Wu X, Zhang Y, Jiang F, Xu Y, Li Y, Wang Q, et al. Effect of efsubaglutide alfa on the pharmacokinetics of metformin and digoxin in healthy participants. Clin Pharmacokinet. 2025;64(9):1367\u201377. https:\/\/doi.org\/10.1007\/s40262-025-01541-0.","journal-title":"Clin Pharmacokinet"},{"key":"1713_CR38","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70262","author":"R Sun","year":"2025","unstructured":"Sun R, Wang Y, Shu H, et al. Biweekly dosing of efsubaglutide alfa maintains glycaemic and continuous glucose monitoring control in type 2 diabetes: a randomised multicentre trial. Diabetes Obes Metab. 2025. https:\/\/doi.org\/10.1111\/dom.70262.","journal-title":"Diabetes Obes Metab"},{"key":"1713_CR39","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.2147\/DDDT.S470826","volume":"18","author":"XD Yang","year":"2024","unstructured":"Yang XD, Yang YY. Clinical pharmacokinetics of semaglutide: a systematic review. Drug Des Devel Ther. 2024;18:2555\u201370. https:\/\/doi.org\/10.2147\/DDDT.S470826.","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"1713_CR40","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/psp4.13099","volume":"13","author":"K Schneck","year":"2024","unstructured":"Schneck K, Urva S. Population pharmacokinetics of the GIP\/GLP receptor agonist tirzepatide. CPT Pharmacometrics Syst Pharmacol. 2024;13(3):494\u2013503. https:\/\/doi.org\/10.1002\/psp4.13099.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"5","key":"1713_CR41","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40262-015-0338-3","volume":"55","author":"JS Geiser","year":"2016","unstructured":"Geiser JS, et al. Clinical pharmacokinetics of dulaglutide in patients with type 2 diabetes: analyses of data from clinical trials. Clin Pharmacokinet. 2016;55(5):625\u201334. https:\/\/doi.org\/10.1007\/s40262-015-0338-3.","journal-title":"Clin Pharmacokinet"},{"key":"1713_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-025-06593-2","author":"D Zhu","year":"2025","unstructured":"Zhu D, et al. Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled. Phase IIb\/III trial Diabetologia. 2025. https:\/\/doi.org\/10.1007\/s00125-025-06593-2.","journal-title":"Phase IIb\/III trial. Diabetologia"},{"key":"1713_CR43","doi-asserted-by":"publisher","DOI":"10.2337\/db25-738-P","author":"Y Bao","year":"2025","unstructured":"Bao Y, et al. 738-P: efficacy and safety of efsubaglutide alfa in patients with obesity or overweight\u2014A phase 2 study. Diabetes. 2025. https:\/\/doi.org\/10.2337\/db25-738-P.","journal-title":"Diabetes"},{"issue":"12","key":"1713_CR44","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1007\/s40262-025-01570-9","volume":"64","author":"Q Wang","year":"2025","unstructured":"Wang Q, Jiang F, Xu Y, Lei Y, Zhang L, Sun X. Exposure-response analysis of efsubaglutide alfa in patients with type 2 diabetes mellitus. Clin Pharmacokinet. 2025;64(12):1785\u201397. https:\/\/doi.org\/10.1007\/s40262-025-01570-9.","journal-title":"Clin Pharmacokinet"},{"key":"1713_CR45","doi-asserted-by":"publisher","first-page":"6222","DOI":"10.1038\/s41467-026-72574-7","volume":"17","author":"W Jia","year":"2026","unstructured":"Jia W, Gao F, Lu J, Cheng Z, Dong X, Shi X, et al. Efsubaglutide alfa added to metformin improves glycaemia with beta-cell functional responses in type 2 diabetes: a randomised, double-blind, placebo-controlled, two-stage adaptive phase 2b\/3 trial (SUPER 2). Nat Commun. 2026;17:6222. https:\/\/doi.org\/10.1038\/s41467-026-72574-7.","journal-title":"Nat Commun"},{"issue":"1","key":"1713_CR46","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/dom.15309","volume":"26","author":"L Ji","year":"2024","unstructured":"Ji L, et al. Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once-weekly semaglutide treatment versus comparators: Post hoc pooled analysis from SUSTAIN 1\u20135, 7\u201310 and SUSTAIN China. Diabetes Obes Metab. 2024;26(1):233\u201341. https:\/\/doi.org\/10.1111\/dom.15309.","journal-title":"Diabetes Obes Metab"},{"key":"1713_CR47","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70429","author":"F Gao","year":"2026","unstructured":"Gao F, Yuan M, Mi N, et al. Efficacy, tolerability, and safety of efsubaglutide alfa in participants with obesity or overweight (LIGHT 1): a randomized, double-blind, placebo-controlled, ascending-dose phase 2a trial. Diabetes Obes Metab. 2026. https:\/\/doi.org\/10.1111\/dom.70429.","journal-title":"Diabetes Obes Metab"},{"key":"1713_CR48","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1007\/s40262-025-01569-2","volume":"64","author":"Q Wang","year":"2025","unstructured":"Wang Q, Jiang F, Xu Y, Lei Y, Zhang L, Sun X. Exposure-response analysis of efsubaglutide alfa in patients with type 2 diabetes treated with metformin. Clin Pharmacokinet. 2025;64:1799\u2013809. https:\/\/doi.org\/10.1007\/s40262-025-01569-2.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1713_CR49","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","volume":"182","author":"L He","year":"2022","unstructured":"He L, Wang T, Chen Q, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder or biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2022;182(5):513\u20139. https:\/\/doi.org\/10.1001\/jamainternmed.2022.0338.","journal-title":"JAMA Intern Med"},{"issue":"4","key":"1713_CR50","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/dom.13172","volume":"20","author":"T Vilsb\u00f8ll","year":"2018","unstructured":"Vilsb\u00f8ll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018;20(4):889\u201397. https:\/\/doi.org\/10.1111\/dom.13172.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1713_CR51","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/dom.12640","volume":"18","author":"Z Milicevic","year":"2016","unstructured":"Milicevic Z, Anglin G, Harper K, et al. Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly dulaglutide. Diabetes Obes Metab. 2016;18(5):533\u201340. https:\/\/doi.org\/10.1111\/dom.12640.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"1713_CR52","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.2337\/dci21-0034","volume":"44","author":"MC Riddle","year":"2021","unstructured":"Riddle MC, Cefalu WT, Evans PH, et al. Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetes Care. 2021;44(10):2438\u201344. https:\/\/doi.org\/10.2337\/dci21-0034.","journal-title":"Diabetes Care"},{"issue":"3","key":"1713_CR53","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1007\/s12325-025-03467-2","volume":"43","author":"R Sun","year":"2026","unstructured":"Sun R, Wang K, Yuan G, Shi B, Wang X, Shao A, et al. Diabetes remission in drug-naive patients with type 2 diabetes after efsubaglutide alfa treatment. Adv Ther. 2026;43(3):1098\u2013108. https:\/\/doi.org\/10.1007\/s12325-025-03467-2.","journal-title":"Adv Ther"},{"key":"1713_CR54","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076410","volume":"384","author":"H Yao","year":"2024","unstructured":"Yao H, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024;384:e076410. https:\/\/doi.org\/10.1136\/bmj-2023-076410.","journal-title":"BMJ"},{"key":"1713_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102181","volume":"64","author":"I Caruso","year":"2023","unstructured":"Caruso I, et al. Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis. EClinicalMedicine. 2023;64:102181. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102181.","journal-title":"EClinicalMedicine"},{"issue":"6","key":"1713_CR56","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s13300-025-01728-5","volume":"16","author":"B Osumili","year":"2025","unstructured":"Osumili B, et al. Efficacy and safety of tirzepatide compared with GLP-1 RAs in patients with type 2 diabetes treated with basal insulin: a network meta-analysis. Diabetes Ther. 2025;16(6):1279\u2013311. https:\/\/doi.org\/10.1007\/s13300-025-01728-5.","journal-title":"Diabetes Ther"},{"issue":"6","key":"1713_CR57","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s11154-023-09825-1","volume":"24","author":"J Andraos","year":"2023","unstructured":"Andraos J, Muhar H, Smith SR. Beyond glycemia: comparing tirzepatide to GLP-1 analogues. Rev Endocr Metab Disord. 2023;24(6):1089\u2013101. https:\/\/doi.org\/10.1007\/s11154-023-09825-1.","journal-title":"Rev Endocr Metab Disord"},{"issue":"6","key":"1713_CR58","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503\u201315. https:\/\/doi.org\/10.1056\/NEJMoa2107519.","journal-title":"N Engl J Med"},{"key":"1713_CR59","doi-asserted-by":"publisher","DOI":"10.2337\/db23-757-P","author":"Q Wang","year":"2023","unstructured":"Zhu D, et al. Diabetologia. 2026.\nhttps:\/\/pubmed.ncbi.nlm.nih.gov\/41272211\/.","journal-title":"Diabetes"},{"issue":"11","key":"1713_CR60","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183.","journal-title":"N Engl J Med"},{"issue":"7","key":"1713_CR61","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1056\/NEJMoa2502081","volume":"393","author":"WT Garvey","year":"2025","unstructured":"Garvey WT, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. N Engl J Med. 2025;393(7):635\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2502081.","journal-title":"N Engl J Med"},{"issue":"7","key":"1713_CR62","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1056\/NEJMoa2502082","volume":"393","author":"MJ Davies","year":"2025","unstructured":"Davies MJ, et al. Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes. N Engl J Med. 2025;393(7):648\u201359. https:\/\/doi.org\/10.1056\/NEJMoa2502082.","journal-title":"N Engl J Med"},{"key":"1713_CR63","doi-asserted-by":"publisher","DOI":"10.2337\/db23-778-P","author":"D Anwar","year":"2023","unstructured":"Anwar D, et al. 778-P: efficacy and safety of supaglutide as add-on to metformin in patients with type 2 diabetes. Diabetes. 2023. https:\/\/doi.org\/10.2337\/db23-778-P.","journal-title":"Diabetes"},{"key":"1713_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010145","author":"JJ Gorgojo-Mart\u00ednez","year":"2022","unstructured":"Gorgojo-Mart\u00ednez JJ, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm12010145.","journal-title":"J Clin Med"},{"issue":"4","key":"1713_CR65","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/dom.12596","volume":"18","author":"S Madsbad","year":"2016","unstructured":"Madsbad S. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2016;18(4):317\u201332. https:\/\/doi.org\/10.1111\/dom.12596.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1713_CR66","doi-asserted-by":"publisher","first-page":"24103","DOI":"10.1038\/s41598-025-09807-0","volume":"15","author":"X Ren","year":"2025","unstructured":"Ren X, et al. Efficacy and safety of GLP-1 agonists in the treatment of T2DM: A systematic review and network meta-analysis. Sci Rep. 2025;15(1):24103. https:\/\/doi.org\/10.1038\/s41598-025-09807-0.","journal-title":"Sci Rep"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01713-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01713-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01713-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:45:40Z","timestamp":1791927940000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01713-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":66,"alternative-id":["1713"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01713-6","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"19 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"QW is the founder of Innogen Pharmaceutical Co., Ltd. RY, FJ and YL are employees of Innogen Pharmaceutical Co., Ltd. HZ declares no competing interests. GJP declares no competing interests.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analysed during the current study. All data discussed are from published or publicly available sources unless explicitly identified as preliminary or data on file.","order":5,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"QW conceptualised the review, supervised the work, interpreted the evidence, and reviewed and edited the manuscript. HZ drafted the initial manuscript and contributed to literature review and manuscript revision. RY, FJ, and YL contributed to literature review, data interpretation, table preparation, and manuscript revision. GJP critically reviewed the manuscript, contributed to independent interpretation of the evidence, and reviewed and edited the manuscript. All authors read and approved the final version of the manuscript.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}